Study demonstrates the Bio-RFID™ sensor can deliver stable, repeatable results in predicting blood glucose concentrations using the Dexcom G6® as a reference device From December 2022 through February ...

Mobix Labs, Inc. (NASDAQ:MOBX) said it has been chosen by a major munitions manufacturer to participate in a feasibility program focused on next-generation smart munitions designed for anti-drone ...

Mobix Labs’ selection marks a meaningful entry into the smart munitions category, an area of defense receiving increasing attention as military systems evolve to address faster, more complex threats.

Clinical trial feasibility studies evaluate if a trial can be successfully conducted at a specific site, considering patient population, resources, and timelines, and typically take one month to ...

IRVINE, Calif.--(BUSINESS WIRE)--Mobix Labs, Inc. (Nasdaq: MOBX), a provider of advanced defense and aerospace technologies, today announced that it has been selected by a major munitions manufacturer ...